Patriot Financial Group Insurance Agency LLC Has $1.45 Million Stock Position in Sanofi $SNY

Key Points

• Patriot Financial Group Insurance Agency LLC increased its stake in Sanofi by 24.3% during the second quarter, holding almost $1.45 million worth of shares.
• Several institutional investors are actively acquiring shares of Sanofi, with a significant increase in positions by firms including Eastern Bank and Golden State Wealth Management.
• Sanofi's stock has received multiple upgrades from analysts, with a current consensus rating of "Buy" and a target price of $62.67.

Patriot Financial Group Insurance Agency LLC increased its stake in Sanofi (NASDAQ:SNY - Free Report) by 24.3% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 29,978 shares of the company's stock after acquiring an additional 5,864 shares during the quarter. Patriot Financial Group Insurance Agency LLC's holdings in Sanofi were worth $1,448,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Accent Capital Management LLC acquired a new position in shares of Sanofi in the first quarter worth approximately $29,000. Eastern Bank lifted its stake in shares of Sanofi by 121.0% in the first quarter. Eastern Bank now owns 548 shares of the company's stock worth $30,000 after acquiring an additional 300 shares during the period. Golden State Wealth Management LLC lifted its stake in shares of Sanofi by 619.3% in the first quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock worth $35,000 after acquiring an additional 545 shares during the period. Banque Transatlantique SA acquired a new position in shares of Sanofi in the first quarter worth approximately $33,000. Finally, Brentview Investment Management LLC acquired a new position in shares of Sanofi in the first quarter worth approximately $42,000. 14.04% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms recently commented on SNY. JPMorgan Chase & Co. raised Sanofi from a "neutral" rating to an "overweight" rating in a research note on Friday, August 8th. Wall Street Zen upgraded Sanofi from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Morgan Stanley upgraded Sanofi from an "equal weight" rating to an "overweight" rating and lifted their target price for the stock from $56.00 to $58.00 in a report on Monday, September 8th. Barclays reiterated an "overweight" rating on shares of Sanofi in a report on Wednesday, July 2nd. Finally, Weiss Ratings reiterated a "hold (c)" rating on shares of Sanofi in a report on Saturday, September 27th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $62.67.

Sanofi Trading Up 1.5%

NASDAQ SNY opened at $50.90 on Friday. The company has a market cap of $124.99 billion, a price-to-earnings ratio of 12.24, a P/E/G ratio of 1.19 and a beta of 0.51. Sanofi has a 52 week low of $44.62 and a 52 week high of $60.12. The business has a 50 day moving average price of $48.19 and a 200-day moving average price of $50.09. The company has a quick ratio of 0.94, a current ratio of 1.27 and a debt-to-equity ratio of 0.19.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing the consensus estimate of $0.96 by ($0.06). The firm had revenue of $11.34 billion for the quarter, compared to the consensus estimate of $9.91 billion. Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The company's revenue was down 7.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.73 EPS. As a group, equities analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.